Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Morphotek, a subsidiary of Eisai, has announced the issuance of US patent no. 7,235,643 B2 that relates to certain methods of enhancing the affinity of monoclonal antibodies.
Subscribe to our email newsletter
The patent illustrates the company’s Morphodoma technology, a whole genome evolution platform that can enhance cells producing monoclonal antibodies to yield daughter cells producing antibodies with enhanced pharmacologic activity.
According to the company, Morphodoma technology enhances evolution within cells through the reversible regulation of the mismatch repair (MMR) pathway, a highly conserved process employed by all living organisms to repair mutations that naturally occur during DNA replication. The company is employing this technology to discover and develop novel proteins and antibodies for treating cancer, inflammatory and infectious diseases.
Philip Sass, executive vice president and chief operating officer of Morphotek, said: “The use of our Morphodoma technology enables our researchers to generate high affinity antibodies from lead target-specific antibodies with low affinity. This platform allows for the rapid and efficient optimization of antibodies for clinical development and proof-of-concept evaluation for use in treating disease.”